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Rationale: There is a lack of consensus on factors that predict mortality in idiopathic pulmo-
nary arterial hypertension (IPAH). Tests that can accurately predict prognosis are needed to
guide treatment and counsel patients.
Methods: We conducted a systematic review to identify factors that prognosticate mortality in
IPAH. Study design, cohort size, comparison method, measured value, and statistical signifi-
cance was extracted for eight pre-selected parameters [pulmonary vascular resistance
(PVR), mean pulmonary arterial pressure (mPAP), mean right atrial pressure (mRAP), cardiac
output, right ventricular end diastolic pressure, functional class, 6 min walk distance
(6MWD), and diffusing capacity of carbon monoxide].
Results: 107 factors have been associated with mortality in IPAH. A reproducible predictive
association with mortality was demonstrated for only 10 factors: functional class (14 studies),
heart rate (10 studies), 6MWD (8 studies), pericardial effusion (5 studies), mPAP (10 studies),
mRAP (17 studies), cardiac index (13 studies), stroke volume index (4 studies), PVR (10
studies), mixed venous PaO2 or saturations (4 studies). Of the 8 factors chosen for detailednce; CO, cardiac output; CI, cardiac index; CPET, cardiopulmonary exercise; DLCO, diffusing capacity
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Factors that prognosticate mortality in idiopathic pulmonary arterial hypertension 1589evaluation, there were at least half as many studies that evaluated the variable and did not
find an association with mortality compared to those that did.
Conclusions: There is a large body of literature describing numerous factors that predict
mortality in IPAH. Most factors have been assessed in very few studies. There are conflicting
reports on the prognostic value of many factors. These discrepancies highlight the need to eval-
uate the literature in total when considering the utility of variables as prognostic factors in IPAH.
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Idiopathic pulmonary arterial hypertension (IPAH) is
a disease of unknown etiology characterized by patholog-
ical changes in the pulmonary vasculature that lead to
increased pulmonary vascular resistance, elevated pulmo-
nary arterial pressures, right ventricular dysfunction, and
early death.1 By consensus IPAH is defined by a mean
pulmonary arterial pressures (mPAP) > 25 mmHg at rest,
a pulmonary capillary wedge pressure (PCWP) less than
15 mmHg, and an elevated pulmonary vascular resistance
(PVR), with no identifiable underlying cause.2,3
IPAH is a devastating and progressive condition with
a poor long term prognosis.4 Given the life limiting nature
of IPAH, the ability to predict disease progression and
death is necessary for optimal care of these patients and
timely intervention. This is particularly true given that the
treatment of last resort for many patients with IPAH is
lung transplantation.5 This intervention is exquisitely
sensitive to timing.6,7 Lung transplant recipients are also
subjected to increase morbidity and mortality and thus
transplanting IPAH patients too early may not increase life
expectancy.8 On the other hand, referral for this proce-
dure too late can result in death while awaiting a suitable
donor thus deny patients an opportunity for an extended
lifespan. Short of transplantation, the most effective
intervention for IPAH remains prostacyclin.5,9 This inter-
vention also require careful consideration of prognosis
and timing as it is administered as a continuous parenteral
infusion and thus carriers a risk of life threatening
complications such as sepsis and hemodynamic collapse if
interrupted.10 Furthermore, many patients are reluctant
to initiate this therapy until absolutely necessary as it is
cumbersome, labor intensive, and intrusive. With the
recent development of oral therapies5 (such as endothelin
receptor antagonists and phosphodiesterase inhibitors) for
less severe disease, prognostication has become no less
important as timely initiation, escalation, combination,and abandonment of these therapies requires an ability to
predict outcome.11
There have been significant advances in our pathophys-
iologic understanding of pulmonary hypertension and the
diagnostic classification of this disease has been revised
a number of times.3 These advances, along with the
development of new therapeutic and pharmacologic inter-
ventions have collectively changed our perspective of IPAH
and the evaluation of these patients. During this time
a number of new investigative techniques and markers of
disease have been developed while older ones have been
advanced, refined, and reevaluated.
Despite the growing number of studies evaluating
prognosis and prognostic factors for mortality in IPAH,
consensus on factors that portend a worse outcome, and
the best method or combination of methods of evaluation,
remain lacking. In part this is due to the fact that IPAH is
a rare and fatal disease. As a result the literature is
dominated by small, often retrospective, studies with
limited power to properly assess effects or compare
multiple outcomes and draw meaningful conclusions. Thus
conclusions from individual studies are difficult to draw
and extrapolate to larger populations without a compre-
hensive view of the literature. Consensus statements have
provided valuable guidance in the evaluation and man-
agement of IPAH patients but have not systematically
reviewed the literature to provide a balanced overview of
the evidence.12,13 The purpose of this study is to system-
atically review the current medical literature to identify
factors that prognosticate mortality in IPAH in an attempt
to aid clinicians and health care professional in the
appropriate evaluation and care of IPAH patients as well as
identifying areas in need of further study. Furthermore,
a comprehensive review of the literature will facilitate the
development of clinically useful composite endpoints for
clinical trials and therefore identification of these markers
is important not only for patient care and epidemiologic
research but also therapeutic clinical trials.
1590 J.R. Swiston et al.Methods and materials
We performed a literature search using MEDLINE and EMBASE
databases (inception to August 2009) to identify original
publications describing factors that prognosticate mortality
in idiopathic pulmonary arterial hypertension (IPAH). We
used the following key terms: “pulmonary hypertension” or
“pulmonary arterial hypertension” or “idiopathic pulmonary
arterial hypertension” and “mortality” or “survival” or
“death”, or “prognosis”. The search was limited to the
English language and human studies. Citations (titles and
abstracts) identified from the literature search were
reviewed to identify publications relevant to the research
question. Complete manuscripts of relevant citations were
obtained for full review. References from extracted manu-
scripts were also reviewed for relevant publications.
Publications were included in the final synthesis if they
described baseline factors that were associated with
mortality in patients with IPAH. IPAH was defined according
to the Venice clinical classification of pulmonary hyper-
tension13 and was consistent with the Dana Point revised
classification.3 Patient populations defined as primary
pulmonary hypertension based on the Evian classification13
were considered to be synonymous with IPAH and included
in the synthesis. Publications were excluded if they did not
describe mortality or survival as an outcome, reported
a composite endpoint only, did not describe outcomes
specifically for IPAH patients (mixed cohorts), or the vari-
ables were described in the context of a change over time
(with or without treatment) rather than a baseline point
evaluation. Case series, interventional studies, observa-
tional studies, and population based analyses were all
included. Abstracts and case reports were excluded.6830 citation
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Figure 1 Summary of literature searcFactors associated with mortality in IPAH were collated
into 6 domains: history and clinical exam features, exercise
parameters, electrocardiographic parameters, clinical
investigations [excluding echocardiography (echo) and
magnetic resonance imaging (MRI)], non-invasive cardiac
parameter (echo and MRI), and invasive hemodymanic
parameters. In addition, 8 parameters were selected a pri-
ori for a more detailed evaluation [PVR, mPAP, mean right
atrial pressure (mRAP), cardiac output (CO), right ventric-
ular end diastolic pressure (RVEDP), World Health Organi-
zation (WHO) or new York Heart Association (NYHA)
functional class, 6 min walk distance (6MWD), and diffusing
capacity of carbon monoxide (DLCO)]. These factors were
selected by the three authors by consensus. For these
parameters, additional information was extracted including
the study design, cohort size, comparison method,
measured value, and statistical significance. Furthermore,
for these 8 parameters all evaluations were extracted
regardless of whether a positive association with mortality
was identified.
All steps in the literature search were carried out inde-
pendently by two reviews (JRS and SRJ). Disagreement
between the two extracting authors was resolved by
consensus. If consensus could not be reached, a third
author (JTG) reviewed the study and a decision to include
the publication was reach by consensus.
Results
The database search identified 6830 citations (Fig. 1).
Review of the titles and abstracts of these citations resul-
ted in 137 publications that were obtained for full review.
Six additional studies were identified from the references
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Table 1 Patient factors and findings reported to prognosticate mortality in IPAH.
Parameter Number of
supporting studies
Citation
History and clinical exam
Sex 1 29
Age at diagnosis 1 39
Age at onset of symptoms 1 39
AfricaneAmerican ethnicity (compared to Caucasian) 1 40
Duration of symptoms at presentation 1 41
Time from onset of symptoms to diagnosis 1 29
Peri-pregnancy presentation 1 20
Initial functional class (WHO or NYHA) 14 4, 14, 15, 18, 19, 21, 22, 25, 29,
33, 39, 42-44
Right heart failure at some stage 2 15, 20
Raynauds phenomenon 2 4
Heart rate (sinus tachycardia) 10 14, 18, 21, 30, 36, 45-49
Exercise parameters
6 min walk test distance 8 15, 18, 19, 25, 32, 33, 35, 49
6MWT trough SaO2 during exercise 1 23
6MWT DSaO2 (diff btwn rest and trough SaO2
5 1 23
Exercise duration 1 21
Peak VO2 (mL Kg
1 min1) 1 21
Peak systolic blood pressure 1 21
Peak heart rate 1 21
PETCO2 at rest 1 21
VE/VCO2 slope 1 21
ECG Criteria
Right ventricular hypertrophy
(number of Sokolow and Lyon criteria)
2 16, 50
Right ventricular hypertrophy (WHO criteria) 1 24
Right ventricular hypertrophy (criteria not specified) 2 17, 39
Mean frontal electrical axis of the P wave 3 16, 50, 51
Right axis deviation 1 20
Right atrial strain 1 20
P wave terminal force in V1 1 51
P wave amplitude in lead II 1 24
P wave amplitude in lead III 1 24
P wave amplitude in aVF 1 24
P wave 0.25 mV in II 1 24
R wave amplitude in V5 2 16, 50
R wave amplitude in V6 2 16, 50
R/S ratio in V5 2 16, 50
R/S ratio in V6 2 16, 50
qR pattern in V1 2 24, 50
S wave amplitude in V6 2 16, 50
Number of chest leads with T wave inversion 1 16
Clinical investigation
Right ventricular enlargement on chest X-ray 1 20
Cardiothoracic ratio on chest X-ray 1 39
Forced vital capacity 1 27
Forced expiratory volume in 1 s 1 29
Diffusing capacity of carbon monoxide 1 4
Hematocrit 1 52
Platelet activity (spontaneous aggregation) 1 53
D-dimer 1 54
Von Willebrand factor level 1 55
Asymmetrical dimethylarginine concentration 1 56
Serum uric acid 3 21, 57, 58
Plasma atrial natriuretic peptide 2 14, 48
(continued on next page)
Factors that prognosticate mortality in idiopathic pulmonary arterial hypertension 1591
Table 1 (continued)
Parameter Number of
supporting studies
Citation
Plasma brain natriuretic peptide 1 14
Plasma norepinephrine 1 14
N-terminal pro-brain natriuretic peptide 1 25
Perfusion lung scintigraphy (mottled appearance) 1 59
Cardiac 123I-MIBG uptake (heart to mediastinum activity ratio) 1 60
C-reactive protein 1 61
Echocardiography and MRI Parameter
Severity of pericardial effusion 5 14, 18, 25, 47, 62
Presence of a pericardial effusion 2 18, 25
RA area index (5 cm/m2) 1 18
Tei index 1 63
RV/LV diastolic area 1 25
LV ejection time 1 64
LV diastolic eccentricity index 1 25
LV systolic eccentricity index 1 25
LV deformity index (longest/shortest diameter of the
LV cavity at the point of max deformity in early systole)
2 14, 57
IVC inspiratory diameter 1 25
Pulmonic flow acceleration time <62 ms 1 47
Tricuspid early flow deceleration 300 cm2/s 1 47
Mitral early flow to atrial flow velocity ratio 1.0 1 47
Stroke volume index (MRI)a 1 19
LVEDVI (MRI)a 1 19
RVEDVI (MRI)a 1 19
Hemodynamic parameters
Mean PAP (mmHg) 10 4, 14, 15, 17, 25, 29, 30, 39, 47, 65
Diastolic pulmonary arterial pressure (mmHg) 2 39, 47
Mean right atrial pressure (mmHg) 17 14, 15, 17-19, 21, 25-27, 29, 30, 35,
36, 39, 46, 49, 56
PCWP (mmHg) 1 26
PCWP/left ventricular end diastolic pressure 1 20
Systolic blood pressure (mmHg) 1 26
Systolic PAP/systolic blood pressure 1 26
Cardiac index (L/min/m2) 13 4, 21, 24, 26-29, 36, 39,
42, 46, 47, 52
Cardiac output (L/min) 3 14, 20, 21
Stroke volume (ml) 1 36
Stroke volume index (ml/beat/m2) 4 19, 27, 30, 46
Right ventricular work index (kg m/min/m2) 2 39, 52
Right ventricular stroke work (mmHg cc) 1 36
Right ventricular end diastolic pressure (mmHg) 3 20, 26, 39
Stroke volume/pulmonary pulse pressure (ml/mmHg) 1 36
Mean pulmonary artery$stroke volume (per 100) 1 36
Pulmonary artery/Aortic artery systolic pressure 1 39
Pulmonary pulse pressure (mmHg) 1 36
Pulmonary capacitance (ml/mmHg) 1 36
Reduced pulmonary artery pulsatility
(by intravascular ultrasound)
1 66
Increased pulmonary/elastic strain index
(by intravascular ultrasound) (mmHg)
1 66
Patent foramen ovale 1 20
Pulmonary vascular resistance (dyn s cm5 or wood units) 10 17, 20, 23-25, 30, 36, 42, 46, 49
Pulmonary vascular resistance index
(dyn s cm5 m2 or wood units/m2)
3 4, 19, 27
Total pulmonary vascular resistance
(mPAP/CO/60  1332) (dynes s cm5)
2 26, 52
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Table 1 (continued )
Parameter Number of
supporting studies
Citation
Systemic vascular resistance (Wood units or dyn s cm5) 3 20, 26, 46
Pulmonary vascular/systemic vascular resistance 3 26, 27, 39
Mixed venous PO2 (mmHg) or O2 saturation (%) 4 18, 19, 27, 56
Pulmonary arterial PO2 (mmHg) or O2 saturation (%) 2 4, 39
Systemic arterial PO2 (mmHg) or O2 saturation (%) 3 21, 39, 52
Systemic venous O2 saturation (%) 2 14, 21
Arterial-venous O2 content difference (% or ml/100 ml) 2 21
Arterial PCO2 (mmHg) 2 29, 30
Acute vasodilator response to prostacyclin 1 67
Acute vasodilator response to calcium channels blockers 1 22
WHOZ World Health Organization; NYHAZ New York Heart Association; 6MWTZ 6 min walk test; COZ cardiac output; O2Z oxygen;
PO2Z partial pressure of oxygen; PCO2Z partial pressure of carbon dioxide; DSaO2Z SaO2 at rest e minimal SaO2 sustained for >10 s
during the 6MWT; VO2Z oxygen uptake during exercise; PETCO2Z end-tidal partial pressure of carbon dioxide; VE/VCO2Z ventilation
to carbon dioxide production during exercise; MIGB Z metaiodobenxylguanidine; RA Z right atrium; RV Z right ventricle; LV Z left
ventricle; IVCZ inferior vena cava; LVEDVIZ LV end diastolic volume index; RVEDVIZ RV end diastolic volume index; PAPZ pulmonary
arterial pressure; mPAP Z mean pulmonary arterial pressure; PCWP Z post-capillary wedge pressure.
a Parameters measured by magnetic resonance imaging (MRI) (all other parameters measured by echocardiography).
Factors that prognosticate mortality in idiopathic pulmonary arterial hypertension 1593lists of these publications. Of these 143 studies, 54 publi-
cations described parameters that were associated with
mortality in IPAH and were included in the final analysis.
From the 54 publications, 107 parameters were identified
that were reported to be associated with mortality in IPAH.
Of the 107 parameters identified, there were 11 history
and clinical exam features, 9 exercise parameters, 18 elec-
trocardiographic parameters, 18 clinical investigations, 16
non-invasive cardiac parameters (echocardiography and
magnetic resonance imaging), and 35 invasive hemodynamic
parameters (Table 1). The majority of these factors were
reported to be associatedwithmortality in only a few studies.
A predictive association with mortality was reproduced in
more than 3 studies for only 10 parameters (Table 2). These 10
parameters were functional class (14 studies), heart rate (10
studies), 6 min walk distance (8 studies), pericardial effusion
severity (5 studies), mPAP (10 studies), mRAP (17 studies),
cardiac index (13 studies), stroke volume index (4 studies),
pulmonary vascular resistance (10 studies), mixed venous
partial pressure of oxygen (PO2) or O2 saturations (4 studies)
(Table 2).Table 2 Prognostic variables with greater than three analyses
Parameters Number of su
studies
Initial functional class (WHO or NYHA) 14
Heart rate (sinus tachycardia) 10
6 min walk test distance 8
Severity of pericardial effusion 5
Mean pulmonary arterial pressure (mmHg) 10
Mean right atrial pressure (mmHg) 17
Cardiac index (L/min/m2) 13
Stroke volume index (ml/beat/m2) 4
Pulmonary vascular resistance
(dyn s cm5 or wood units)
10
Mixed venous PO2 (mmHg) or O2 saturation (%) 4
WHO Z World Health Organization; NYHA Z New York Heart AssociaThe eight pre-defined parameters that were chosen for
a more detailed analysis are shown in Table 3. This table
also includes the citations for the studies that found an
association of the parameter with mortality as well as the
studies that did not. Twenty seven publications reported
analyses of the prognostic implications of mPAP for
mortality in IPAH. Ten studies found an association between
this parameter and mortality while 19 studies did not
(Table 4). Two of these studies found an association with
mortality in the univariable analysis that was lost when
other parameters were corrected for in the mulitvariable
analysis.14,15 One study found an inverse correlation
between mortality and mPAP wherein a lower value was
associated with a higher mortality.15 There was significant
heterogeneity in the methods of analysis. Within the most
common method of evaluation, the Cox proportional hazard
model, variations were seen in the analysis with some
studies correcting for other variables and other not, some
studies using cutoff values for mPAP, and some studies using
a per unit analysis (mmHg). Many studies did not report the
unit of analysis.reporting an association with mortality in IPAH.
pporting Citation
4, 14, 15, 18, 19, 21, 22, 25, 29, 33, 39, 42-44
14, 18, 21, 30, 36, 45-49
15, 18, 19, 25, 32, 33, 35, 49
14, 18, 25, 47, 62
4, 14, 15, 17, 25, 29, 30, 39, 47, 65
14, 15, 17-19, 21, 25-27, 29, 30, 35,
36, 39, 46, 49, 56
4, 21, 24, 26-29, 36, 39, 42, 46, 47, 52
19, 27, 30, 46
17, 20, 23-25, 30, 36, 42, 46, 49
18, 19, 27, 56
tion; PO2 Z partial pressure of oxygen; O2 Z oxygen.
Table 3 Significant and non-significant associations of eight parameters described to be associated with mortality in IPAH.
Prognostic factor Number of
supporting
publications
Supporting citations Number of
non-supporting
publications
Non-supporting
citations
Mean pulmonary arterial pressure
(mmHg)
10 4, 14, 15, 17, 25, 29, 30,
39, 47, 65
19 14, 15, 18-20, 22-24,
26-28, 33, 35, 36,
42, 46, 49, 52, 56
Mean right atrial pressure (mmHg) 17 14, 15, 17-19, 21, 25-27,
29, 30, 35, 36, 39, 46, 49, 56
11 17-20, 23, 24, 26,
28, 33, 47, 52
Cardiac output (L/min) 3 14, 20, 21 6 14, 21-25
Right ventricular end diastolic
pressure (mmHg)
3 20, 26, 39 4 20, 26-28
Pulmonary vascular resistance
[(dynes s cm5 or Woods units
(mmHg/L/min)]
10 17, 20, 23-25, 30, 36,
42, 46, 49
7 18, 20-22, 29, 47, 56
Functional class (WHO or NYHA) 14 4, 14, 15, 18, 19, 21, 22,
25, 29, 33, 39, 42-44
11 4, 14, 15, 18, 19, 23,
24, 28, 35, 36, 57
6 min walk test distance (m) 8 15, 18, 19, 25, 32, 33, 35, 49 4 15, 18, 23, 36
Diffusing capacity of CO
(mL/min/mmHg)
1 4 2 4, 23
WHO Z World Health Organization; NYHA Z New York Heart Association; CO Z carbon monoxide.
1594 J.R. Swiston et al.For mRAP, 17 studies were identified that supported this
parameter as a prognostic factor for mortality in IPAH while
11 studies did not find an association (Table 5). Four studies
reported an association between mRAP and mortality by
some analyses but not others within the same study.16e19 As
with mPAP there was significant heterogeneity in the type
of statistical analysis employed.
For cardiac output only 3 analyses were identified that
supported this parameter as a prognostic factor for
mortality in IPAH (Table 6).14,20,21 Two of these studies
(Nagaya et al.14 and Wensel et al.21) identified an associa-
tion between CO and mortality in their univariable analysis
that was lost when the analysis was corrected for other
factors in the multivariable analyses.14,21 Four other studies
were identified that did not find an association between CO
and mortality.22e25
For RVEDP, only 3 studies were identified that supported
this parameter as a prognostic factor for mortality in
IPAH20,26 (Ref.15,18,38) (Table 7). However two of these
(Rozkovec et al.20 and Kanemoto et al.26) also reported the
absence of an association depending on the type of analysis
performed or the definition of survival that was used. Two
other studies did not detect any association between RVEDP
and mortality.27,28
For PVR, 10 studies were identified that supported this
parameter as a prognostic factor for mortality in IPAH while
7 studies did not find an association (Table 8). Only one
study by Rozkovec and colleagues, depending on the type
of analysis chosen, reported both an association and a lack
of association within the same study.20
For functional class, 14 studies were identified that
supported this parameter as a prognostic factor for
mortality in IPAH while 11 studies did not find an association
(Table 9). Five studies reported both association and the
lack of association for functional class within the same
study depending on the type of analysis used.4,14,15,18,19
Many studies grouped functional classes together for anal-
ysis while others compared only some classes to others.Ten studies have evaluated 6MWD for potential as
a prognostic factor for mortality in IPAH. Eight studies were
identified that supported this parameter as a prognostic
factor for mortality in IPAH while 4 studies did not find an
association (Table 10). Two of these studies reported an
association by univariable analysis that was lost in the
multivariable model.15,18 There was significant variation in
the unit of analysis with some studies using absolute cutoffs
while others used blocks of distance such as 50 m. Many
studies did not report the unit of analysis.
For DLCO, only 2 studies have evaluated and reported
the prognostic power of the parameter for mortality in IPAH
(Table 11).4,23 Of those, one study found an association
between this parameter and mortality by univariable
analysis but the significance of the association was lost
when other variables were accounted for in the multivari-
able analysis.4 The only other study that evaluated DLCO
did not detect an association with mortality.23
Discussion
Through a systematic review of the literature, we identified
107 patient related factors reported to predict mortality in
IPAH. Despite this large number of studies, only 10 of these
factors are supported by more than 3 studies. Sixty nine
factors were described as prognostic variables for mortality
in IPAH in only a single study. Mean RAP was the variable
most commonly reported to be associated with mortality
followed by functional class, cardiac index, heart rate,
mPAP, PVR, 6MWD, pericardial effusion, mixed venous PO2
or O2 saturation, and stroke volume index.
Invasive hemodynamic variables were the most
frequently reported group of prognostic factors in the
current literature with 35 hemodynamic variables reported
to have an association with mortality, 6 of which had
greater than 3 supporting studies. However, mPAP, CO, and
REVDP all had more analyses that did not find a predictive
association compared to those that did. In fact, for mPAP
Table 4 Studies evaluating the relationship between survival and mean pulmonary arterial pressure in IPAH.
Study Association Comparison Measured value (mean
pulmonary arterial pressure)
Significance Study Design Number of
patients
Loogen65 þ t test (independent random samples) 50.8  3.4 (survivors) vs
69.0  5.8 (nonsurvivors) (mean  SE)
P < 0.05 RC 24
Eysmann47 þ Univar Cox life table analysis 53  15 (survivors) vs
65  15(nonsurvivors) (mean  SD)
P Z 0.04 CNS 26
Chapman17 þ Univar analysis (Wilcoxon test) NR P Z 0.0006 RC 22
ManneWhitney U test and Fisher’s
exact test
84 (survival <12 mth) vs
61 (survival >40 mth)
P < 0.05
D’alonzo4 þ Univar analysis (proportional
hazard analysis)
OR 1.16 (1.05, 1.28)b NR PC 194
Multivar analysis (proportional
hazard analysis)
OR 1.02 (1.01, 1.03)b NR
Rajasekhar39 þ Student t test 54.9  16.7 (survivors) vs
66.6  17.7 (non survivors) (mean  SD)
P Z 0.028 RC 61
Okada30 þ Univar analysis
(ManneWhitney U test)
54.4  17.0 (survivors) vs 66.5  16.1
(non survivors) (mean  SD)
P Z 0.001 RC 223
Nagaya14 þ Univar analysis (Cox proportional
hazard regression)
RR 1.043 (1.00, 1.088)b P Z 0.0497 PC 60
Appelbaum29 þ Univar analysis (proportional
hazard model)
NR (reported only as affecting survival) NR RC 44
Sitbon15 þ Univar analysis (Proportional
hazard model)
HR 1.72 (1.04, 2.86)a Cutoff <65 mmHg P Z 0.036 RC 178
Fijalkowska25 þ Univar analysis (Cox proportional
hazard model)
HR 1.03 (1.0, 1.06)b P Z 0.0337 PC 36
Kanemoto52  T test 62.9  17.8 (alive) vs 61.8  16.9 (dead) NS CS 113
Rich46  Unpaired student t test 53  9 (survivors) vs
74  27 (nonsurvivors) (mean  SD)
NS PC 12
Rich22  Stepwise Cox regression analysis NR NS PC 23
Rozkovec20  One tailed Fisher’s exact test or
Student t test
60.75  22.43 (survival >5 yrs) vs
63.89  12.31 (survival<5 yrs)
(mean  SD)
NS RC 34
 Spearman’s rank correlation
to survival time (one tailed)
NR NS
Kanemoto26  Unpaired student t test I 61  4 (survial <3 mths)c vs
IV 54  3 (survival >24 mths)c
NS CNS 87
Unpaired student t test II 58  3 (survival 4e12 mths)c vs
IV 54  3 (survival >24 mths)c
NS
Unpaired student t test III 58  6 (survival 13e24 mths)c vs
IV 54  3 (survival >24 mths)c (mean  SE)
NS
Dolara42  Log rank test Not correlated to survival Cutoff
50 mmHg
NR RC NR
(continued on next page)
F
a
cto
rs
th
a
t
p
ro
gn
o
stica
te
m
o
rta
lity
in
id
io
p
a
th
ic
p
u
lm
o
n
a
ry
a
rte
ria
l
h
yp
e
rte
n
sio
n
1595
Table 4 (continued)
Study Association Comparison Measured value (mean
pulmonary arterial pressure)
Significance Study Design Number of
patients
Sandoval27  Univar analysis (Proportional
hazard model)
HR 2.08 (0.85, 5.10)b P Z 0.105 PC 61
Nagaya14  Multivar analysis (Cox regression) NS NS PC 60
Chun28  Univar analysis (Cox proportional
hazard model)
HR 0.98 (0.91, 1.10)b P Z 0.76 CNS 13
Paciocco23  Unpaired t-test 55  9 (survivors) vs
59  12 (non survivors) (mean  SD)
NS PC 34
Multivar analysis (Cox regression) HR 1.23 (1.03, 1.47)b P Z 0.33
Bossone24  Univar analysis (Cox proportional
hazard model)
HR 1.03 (0.98, 1.08) Per mmHg P Z 0.25 PC 51
Raymond18  Univar analysis (Cox proportional
hazard model)
HR 1.30 (0.76, 2.24) Per
15 mmHg
P Z 0.344 PC 81
Sitbon15  Multivar analysis (Cox proportional
hazard regression)
NR NS RC 178
Kielstein56  2 tailed t test 54  13 (survivors) vs
56  15 (nonsurvivors) (mean  SD)
NS PC 57
McLaughlin33  Univar analysis (Cox proportional
hazard model)
HR 1.4 (0.6, 3.6) Cutoff 54 mmHg NR PC 169
Mahapatra36  Wilcoxon rank sum test 51  11 (survivors) vs
54  10 (nonsurvivors)
P Z 0.3273 PC 104
Univar analyis (Cox proportional
hazard model)
HR 1.02 (0.98, 1.05)b P Z 0.2586
Provencher35  Univar analysis (Cox proportional
hazard model)
HR 1.01 (0.96, 1.06)b P Z 0.642 RC 103
Van Wolferen19  Univar analysis (Cox proportional
hazard model)
HR 1.03(0.41, 2.60)b P Z 0.941 PC 64
Henkens49  t test or chi-square test 53  13 (survivors) vs
53  16 (nonsurvivors)
P Z 0.90 RC 140
Significance results were defined as a p value <0.05 and 95% confidence intervals that did not include 1.
All mean pulmonary arterial pressure values reported in mmHg.
UnivarZ univariable; MultivarZmultivariable; PCZ prospective cohort; RCZ retrospective cohort; CSZ cross sectional study; CNSZ cohort type not specified or determined from the
reported study; NSZ not significant (value not provided); NRZ value not reported; ORZ odds ratio; RRZ relative risk; HRZ hazard ratio; Bracketed numbers following odds ratios or
hazard ratios indicate 95% confidence intervals; Mths Z months; Yrs Z years.
a inverse association (higher mortality associated with a lower mPAP).
b A cutoff value or number of units used for comparison was not explicitly defined.
c From time of right heart catheterization.
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Table 5 Studies reporting evaluating the relationship between survival and mean right atrial pressure in IPAH.
Study Association Comparison Measured value (mean
right atrial pressure)
Significance Study
Design
Number of
patients
Rich46 þ Unpaired student t test 6  2 (survivors) vs
17  6 (nonsurvivors) (mean  SD)
P < 0.01 PC 12
Kanemoto26 þ Unpaired student t test I 13  3 (survival <3 mths)b vs
IV 6  1(survival >24 mths)b (mean  SE)
P Z 0.01 CNS 87
Chapman17 þ Multivar analysis (Cox proportional
hazards regression)
NR P Z 0.0307 RC 22
Rajasekhar39 þ Student t test 6.0  3.3 (survivors) vs
9.5  5.6 (non survivors) (mean  SD)
P Z 0.023 RC 61
Student t test 5.9  2.2 (survival >2 years) vs
11.2  5.8 (survival 2 years)
P Z 0.002
Life table survival analysis (Lee Desu statistics) 63 mths vs 13 mths
(median survival) (RAP cutoff  7 mmHg)
P Z 0.005
Sandoval27 þ Univar analysis (Proportional hazard model) HR 3.87 (1.59, 9.44)a P Z 0.004 PC 61
Multivar analysis (Cox Proportional
hazard regression)
HR 4.30 (1.20, 15.4)a P Z 0.02
Okada30 þ Univar analysis (ManneWhitney U test) 5.4  5.2 (survivors)
vs 8.0  4.9 (non survivors) (Mean  SD)
P Z 0.001 RC 223
Nagaya14 þ Univar analysis (Cox proportional hazard regression) RR 1.153 (1.035, 1.284)a P Z 0.0095 PC 60
Appelbaum29 þ Univar analysis (proportional hazard model) NR (reported only as affecting survival) NR RC 44
Raymond18 þ Univar analysis (Cox proportional hazard model) HR 1.52 (1.13, 2.05) Per 5 mmHg P Z 0.004 PC 81
Sitbon15 þ Univar analysis (Proportional hazard model) HR 2.74 (1.58, 4.75) Cutoff 12 mmHg P Z 0.0003 RC 178
Multivar analysis (Cox proportional
hazard regression model)
NR NR
Wensel21 þ Univar analysis (Cox proportional hazard model) HR 1.118 (1.060, 1.179)a P Z 0.0001 PC 86
Multivar analysis (Cox proportional hazard model) HR 1.076 (CI NR)a P < 0.05
Kielstein56 þ 2 tailed t test 7.5  5.1 (survivors) vs
12.3  7.1 (nonsurvivors) (mean  SD)
P < 0.05 PC 57
Fijalkowska25 þ Univar analysis (Cox proportional hazard model) HR 1.15 (1.04, 1.27)a P Z 0.0045 PC 36
Multivar analysis (Cox proportional hazard model) HR 15.4 (1.38, 165)a P Z 0.024
Mahapatra36 þ Wilcoxon rank sum test 12  6.8 (survivors)
vs 16  6.1 (nonsurvivors)
P Z 0.0193 PC 104
Univar analysis (Cox proportional hazard model) HR 1.07 (1.01, 1.13)a P Z 0.0158
Provencher35 þ Univar analysis (Cox proportional hazard model) HR 0.90 (0.81, 0.99)a P Z 0.034 RC 103
Van Wolferen19 þ Univar analysis (Cox proportional hazard model) HR 2.85 (1.15, 7.28)a P Z 0.024 PC 64
Henkens49 þ Independent t test or chi-square test 8  5 (survivors) vs 11  6 (nonsurvivors) P Z 0.01 RC 140
Kanemoto52  Student t test 7.2  4.6 (alive) vs 9.2  7.4 (dead) NS CS 113
Rozkovec20  One tailed Fisher’s exact test or Student t test 8.00  4.63 (survival >5 yrs) vs
7.56  3.55 (survival <5 yrs) (mean  SD)
NS RC 34
Spearman’s rank correlation to
survival time (one tailed)
NR NS
(continued on next page)
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Table 5 (continued)
Study Association Comparison Measured value (mean
right atrial pressure)
Significance Study
Design
Number of
patients
Kanemoto26  Unpaired student t test II 6  1 (survival 4e12 mths)b vs
IV 6  1 (survival >24 mths)b
NS CNS 87
Unpaired student t test III 6  1 (survival 13e24 mths)b vs
IV 6  1 (survival >24 mths)b (mean  SE)
NS
Eysmann47  Univar analysis (Cox life table) 9  7 (survivors) vs
13  7 (nonsurvivors) (mean  SD)
P Z 0.08 CNS 26
Chapman17  Univar analysis (Wilcoxon test) NR P Z 0.7560 RC 22
ManneWhitney U test or Fisher’s exact test 9 (survival <12 mth) vs
9 (survival >40 mth)
NS
Chun28  Univar analysis (Cox proportional hazard model) HR 1.03 (0.62, 1.17)a P Z 0.89 CNS 13
Paciocco23  Unpaired t-test 11  6 (survivors) vs
14  5 (non survivors) (mean  SD)
NS PC 34
Multivar analysis (Cox regression) HR 1.09 (0.95, 1.24)a P Z 0.19
Bossone24  Univar analysis (Cox proportional hazard model) RR 1.08 (1.00,1.16) Per mmHg P Z 0.05 PC 51
Raymond18  Multivar analysis (Cox proportional hazard model) NR NS PC 81
McLaughlin33  Univar analysis (Cox proportional hazard model) HR 1.9 (0.7, 4.8) Cutoff >8.5 NS PC 169
Van Wolferen19  Multivar analysis (Cox proportional hazard model) HR 1.074(CI NR)a P Z 0.203 PC 64
Significance results were defined as a p value <0.05 and 95% confidence intervals that did not include 1.
All mean right atrial pressure values reported in mmHg.
Bracketed numbers following odds ratios or hazard ratios indicate 95% confidence intervals.
Univar Z univariable; Multivar Z multivariable; CI Z confidence interval; PC Z prospective cohort; RC Z retrospective cohort; CS Z cross sectional study; CNS Z cohort type not
specified or determined from the reported study; NS Z not significant (value not provided); NR Z value not reported; OR Z odds ratio; RR Z relative risk; HR Z hazard ratio;
Mths Z months; Yrs Z years.
a A cutoff value or number of units used for comparison was not explicitly defined.
b from time of right heart catheterization.
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Table 6 Studies reporting evaluating the relationship between survival and cardiac output in IPAH.
Study Association Comparison Measured value Significance Study
Design
Number of
patients
Rozkovec20 þ One tailed Fisher’s exact test or Student t test 3.56  1.14 (survival >5 yrs) vs
2.77  0.44 (survival <5 yrs)
(mean  SD)
P < 0.01 RC 34
Spearman’s rank correlation to survival
time (one tailed)
NR P < 0.0005
Nagaya14 þ Univar analysis (Cox proportional hazard regression) RR 0.447 (0.226, 0.885)a P Z 0.0209 PC 60
Wensel21 þ Univar analysis (Cox proportional hazard model) HR 0.684 (0.491, 0.952)a P Z 0.017 PC 86
Rich22  Stepwise Cox regression analysis NR NS PC 23
Nagaya14  Multivar analysis (Cox regression model) NR NS PC 60
Paciocco23  Unpaired t-test 4  1.5 (survivors) vs
3.4  1.6 (non survivors)
(mean  SD)
P Z 0.11 PC 34
Multivar analysis (Cox regression model) HR 0.66 (0.38, 1.14)a P Z 0.14
Bossone24  Univar analysis (Cox proportional hazard model) RR 0.63 (0.39, 1.03) Per L/m P Z 0.06 PC 51
Wensel21  Multivar analysis (Cox proportional hazard model) NR NS PC 86
Fijalkowska25  Univar analysis (Cox proportional hazard model) HR 0.52 (0.26, 1.04)a P Z 0.0661 PC 36
Significance results were defined as a p value <0.05 and 95% confidence intervals that did not include 1.
All cardiac output values reported in L/min.
Bracketed numbers following odds ratios or hazard ratios indicate 95% confidence intervals.
UnivarZ univariable; MultivarZ multivariable; PCZ prospective cohort; RCZ retrospective cohort; NSZ not significant (value no provided); NRZ value not reported; RRZ relative
risk; HR Z hazard ratio; Yrs Z years.
a A cutoff value or number of units used for comparison was not explicitly defined.
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Table 7 Studies reporting the relationship between survival and right ventricular end diastolic pressure (RVEDP) in IPAH.
Study Association Comparison Measured value (right ventricular
end diastolic pressure)
Significance Study
Design
Number of
patients
Rozkovec20 þ Spearman’s rank correlation to
survival time (one tailed)
NR P < 0.025 RC 34
Kanemoto26 þ Unpaired student t test I 13  2 (survival <3 mths)b vs
IV 8  1 (survival >24 mths)b
P Z 0.005 CNS 87
Unpaired student t test 11  1 (survival 2 yrs) vs
8  1 (survival >2 yrs) (mean  SE)
P Z 0.05
Rajasekhar39 þ Student t test 8.7  4.2 (survivors) vs
13.8  6.8 (nonsurvivors) (mean  SD)
P Z 0.009 RC 61
Student t test 9.4  3.2 (survival >2 yrs) vs
15.7  7.1 (survival 2 yrs)
P Z 0.003
Life table analysis (Lee Desu statistics) 63 mths vs 13 mths (median survival)
(RVEDP Cutoff  10 mmHg)
P Z 0.0002
Rozkovec20  One tailed Fisher’s exact test or Student t test 11.00  5.91 (survival >5 yrs)
vs 12.29  4.38 (survival <5 yrs) (mean  SD)
NS RC 34
Kanemoto26  Unpaired student t test II 9  2 (survival 4e12 mths)b vs
IV 8  1 (survival >24 mths)b
NS CNS 87
Unpaired student t test III 10  1(survival 13e24 mths)b vs
IV 8  1 (survival >24 mths)b (mean  SE)
NS
Sandoval27  Univar analysis (proportional hazard model) HR 2.34 (0.98, 5.58)a P Z 0.055 PC 61
Chun28  Univar analysis (Cox proportional hazard model) HR 0.96 (0.79, 1.17)a P Z 0.72 CNS 13
Significance results were defined as a p value <0.05 and 95% confidence intervals that did not include 1.
All right ventricular end diastolic pressure values reported in mmHg.
Bracketed numbers following odds ratios or hazard ratios indicate 95% confidence intervals.
UnivarZ univariable; MultivarZ multivariable; PCZ prospective cohort; RCZ retrospective cohort; CNSZ cohort type not specified or determined from the reported study; NSZ not
significant (value not provided); NR Z value not reported; HR Z hazard ratio; Mths Z months; Yrs Z years.
a A cutoff value or number of units used for comparison was not explicitly defined.
b from time of right heart catheterization.
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Table 8 Studies evaluating the relationship between survival and pulmonary vascular resistance in IPAH.
Study Association Comparison Measured value (pulmonary
vascular resistance)
Significance Study
Design
Number of
patients
Rich46 þ Unpaired student t test 20  4 (survivors) vs
57  31 (nonsurvivors) (mean  SD) WU
P < 0.01 PT 12
Rozkovec20 þ Spearman’s rank correlation to survival
time (one tailed)
NR P < 0.005 RC 34
Dolara42 þ Logrank test 5 year survival probability
(15 WU vs >15 WU)
P < 0.01 RC 76
Chapman17 þ Univariate analysis (Wilcoxon test) NR P Z 0.001 RC 22
Multivar analysis (Cox proportional
hazards regression)
NR P Z 0.0017
ManneWhitney U test and Fisher’s exact test 25 (survival <12 month) vs
13 (survival >40 month) (mean) WU
P < 0.05
Okada30 þ Univar analysis (ManneWhitney U test) 1019  528 (survivors) vs
1608  854 (non survivors)
(mean  SD) (dynes$sec$cm5)
P Z 0.002 RC 223
Paciocco23 þ Unpaired t-test 11.9  4.7 (survivors) vs
15.5  6.0 (non survivors) (mean  SD) WU
P Z 0.04 PC 34
Univar analysis (Cox regression analysis) HR 1.12 (1.01, 1.26)b WU P Z 0.04a
Bossone24 þ Univar analysis (Cox proportional hazard model) HR 1.11 (1.02,1.21) Per WU P Z 0.017 PC 51
Fijalkowska25 þ Univar analysis (Cox proportional hazard model) HR 1.08 (1.0, 1.17)b WU P Z 0.0321 PC 36
Mahapatra36 þ Wilcoxon rank sum test 1152  582 (survivors) vs
1639  767 (nonsurvivors) (mean  NR)
(dynes$sec$cm5)
P Z 0.0018 PC 104
Univar analysis (Cox proportional hazard model) HR 1.05 (1.01,1.09)b P Z 0.0038
Henkens49 þ t test or chi-square test 859  455 (survivors) vs
1165  610 (nonsurvivors) (mean  SD)
(dynes$sec$cm5)
P Z 0.01 RC 140
Rich22  Stepwise Cox regression analysis NR WU NS PT 23
Rozkovec20  One tailed Fisher’s exact test or Student’s t test 16.95  9.35 (survival >5 yrs) vs
20.66  4.84 (survival <5 yrs) (mean  SD) WU
NS RC 34
Eysmann47  Univar Cox life table analysis NR P Z 0.08 CNS 26
Appelbaum29  Univar analysis (Cox proportional hazard model) Reported as lacking association
(statistics not shown)
NR RC 44
Raymond18  Univar analysis (Cox proportional hazard model) HR 1.13 (0.82, 1.55) per 5 WU P Z 0.458 PC 81
Wensel21  Univar analysis (Cox proportional hazard model) HR 1.000 (1.000, 1.001)b P Z 0.006 PC 86
Kielstein56  2 tailed t test 1028  489 (survivors) vs
1259  648(nonsurvivors) (mean  SD)
(dynes$sec$cm5)
P > 0.05 PC 57
Significance results were defined as a p value <0.05 and 95% confidence intervals that did not include 1.
Pulmonary vascular resistance units in dyn s cm5 unless otherwise stated.
Bracketed numbers following odds ratios or hazard ratios indicate 95% confidence intervals.
Univar Z univariable; Multivar Z multivariable; WU Z woods units; PT Z prospective trial; PC Z prospective cohort; RC Z retrospective cohort; CNS Z cohort type not specified or
determined from the reported study; NS Z not significant (value not provided); NR Z value not reported; OR Z odds ratio; HR Z hazard ratio.
a not significant after adjusting for the difference between resting and trough oxygen saturation on 6 min walk test (P Z 0.06).
b A cutoff value or number of units used for comparison was not explicitly defined.
F
a
cto
rs
th
a
t
p
ro
gn
o
stica
te
m
o
rta
lity
in
id
io
p
a
th
ic
p
u
lm
o
n
a
ry
a
rte
ria
l
h
yp
e
rte
n
sio
n
1601
Table 9 Studies evaluating the relationship between survival and functional class (New York Heart Association or World Health Organization) in IPAH.
Study Association Comparison Measured value (Functional class) Significance Study
Design
Number of
patients
Rich22 þ Stepwise Cox regression Regression coefficient 2.07 P Z 0.002 PT 23
Dolara42 þ Log rank test 5 year survival probably P < 0.001 RC 86
11% vs 52%
Class II/III vs IV
D’alonzo4 þ Univar analysis (Cox proportional hazards model) OR 2.38 (1.45 3.88) Class IV vs I/II/III NR PC 194
Univar analysis (Cox proportional hazards model) OR 1.93 (1.17, 3.17) Class III/IV vs I/II NR
Rajasekhar39 þ Life table survival analysis (Lee Desu statistics) Class I 126 mths P Z 0.0001 RC 61
Class II 35 mths
Class III 11 mths
Class IV 9 mths (median survival)
Nagaya14 þ Univar analysis (Cox regression analysis) RR 3.922 (1.629, 9.439)a P Z 0.0023 PC 60
Appelbaum29 þ Univar analysis (Cox proportional hazard model) NR Class IV vs I/II/III P < 0.01 RC 44
Raymond18 þ Univar analysis (Cox proportional hazard model) HR 3.25 (1.35, 7.82) Class IV vs I/II/III P Z 0.005 PC 81
Sitbon15 þ Univar analysis (Cox proportional hazard model) HR 2.24 (1.34, 3.73) Class IV vs III P Z 0.002 RC 178
Wensel21 þ Univar analysis (Cox proportional hazard model) NR NR PC 86
McLaughlin33 þ Univar analysis (Cox proportional hazard model) HR 3.2 (1.1, 9.7) Class IV vs I/II/III NR PC 169
Barst43 þ Proportional hazard model HR 5.35 (1.96, 14.56) Class IV vs III P Z 0.001 PC 412
HR 8.74 (2.23, 34.21) Class IV vs II P Z 0.002
Fijalkowska25 þ Univar analysis (Cox proportional hazard model) HR 5.33 (1.33, 21.4)a P Z 0.0181 PC 36
Jing44 þ Log rank test Class I/II vs III/IV P Z 0.02 PC 72
Van Wolferen19 þ Univar analysis (Cox proportional hazard model) HR 2.96 (1.34, 15.8)a P Z 0.015 PC 64
D’alonzo4  Multivar analysis (Cox proportional hazards model) OR 1.69 (0.91, 3.13) (model 1) NS PC 194
OR 1.67 (0.91, 3.05) (model 2)
OR 1.50 (0.79, 2.83) (model 3)
Class IV vs I/II/III
Nagaya57  Multivar analysis (Cox proportional hazard model) RR 1.874 (0.853, 4.120)a P Z 0.1180 CC 90
Nagaya14  Multivar analysis (Cox regression Analysis) RR 1.530 (CI NR)a P Z 0.4761 PC 60
Chun28  Univar analysis (Cox proportional hazard model) HR 3.20 (0.61, 16.74) Class II/IV P Z 0.16 CNS 13
Paciocco23  Univar analysis (Cox regression analysis) HR 0.60 (0.11, 3.20)a P Z 0.55 PC 34
Bossone24  Univar analysis (Cox proportional hazard model) HR 2.04 (0.46, 8.97) Class III/IV vs II P Z 0.347 PC 51
Raymond18  Multivar analysis (Cox proportional hazard model) NR NS PC 81
Sitbon15  Multivar analysis (Cox proportional hazard regression) Risk ratio not reported Class IV vs III NS RC 178
Mahapatra36  Univar analysis (Cox proportional hazard model) HR 0.9 (0.5, 1.6)a P Z 0.6917 PC 104
Provencher35  Univar analysis (Cox proportional hazard model) HR 0.65 (0.14, 2,94) Class IV vs III P Z 0.574 RC 103
Van Wolferen19  Multivar analysis (Cox proportional hazard model) HR 1.211 (CI NR)a P Z 0.703 PC 64
Significance results were defined as a p value <0.05 and 95% confidence intervals that did not include 1.
Class IeIV Z New York Heart Association functional class or World Health Organization functional class.
Bracketed numbers following odds ratios or hazard ratios indicate 95% confidence intervals.
Univar Z univariable; Multivar Z multivariable; CI Z confidence interval; PT Z prospective trial; PC Z prospective cohort; RC Z retrospective cohort; CC Z case control study;
CNSZ cohort type not specified or determined from the reported study; NSZ not significant (value not provided); NRZ not reported; ORZ odds ratio; RRZ relative risk; HRZ hazard
ratio.
a A cutoff value or number of units used for comparison was not explicitly defined.
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Table 10 Studies evaluating the relationship between survival and 6 min walk distance in IPAH.
Study Association Comparison Measured value (6 min walk distance) Significance Study
Design
Number of
patients
Miyamoto32 þ Multivar analysis (Cox proportional hazard model) HR 0.986 (0.973, 0.999) (Cutoff 332 m) P Z 0.0381 PC 43
Raymond18 þ Univar analysis (Cox proportional hazard model) HR 0.36 (0.20, 0.66) (Cutoff 500 ft) P Z 0.001 PC 81
Sitbon15 þ Univar analysis (Proportional hazard model) HR 2.20 (1.31, 3.69) (Cutoff 250 m) P Z 0.003 RC 178
McLaughlin33 þ Univar analysis (Cox proportional hazard model) HR 4.0 (1.3, 12.2) (Cutoff 358 m) NR PC 169
Fijalkowska25 þ Univar analysis (Cox proportional hazard model) HR 0.99 (0.98, 0.99)a P Z 0.0062 PC 36
Provencher35 þ Univar analysis (Cox proportional hazard model) HR 1.42 (1.16, 1.84) (per 50 m) P Z 0.002 RC 103
Van Wolferen19 þ Univar analysis (Cox proportional hazard model) HR 0.33 (0.15, 0.93)a P Z 0.036 PC 64
Multivar analysis (Cox proportional hazard model) HR 0.949 (CI NR)a P Z 0.011
Henkens49 þ t test or chi-square test 404  132 m (survivors) vs
326  120 m (nonsurvivors)
P < 0.001 RC 140
Paciocco23  Univar analysis (Cox regression analysis) HR 0.82 (0.63, 1.05) (per 50 m) P Z 0.11 PC 34
Raymond18  Multivar analysis (Cox proportional hazard model) HR 0.56 (0.29, 1.08) (Cutoff 500 ft) P Z 0.082 PC 81
Sitbon15  Multivar analysis (Cox proportional hazard model) NR (Cutoff <250 m) NS RC 178
Mahapatra36  Wilcoxon rank sum test 334  82 m (survivors) vs
299  111 m (nonsurvivors)
P Z 0.179 PC 104
Univar analysis (Cox proportional hazard model) HR 0.99 (0.99, 1.00)a P Z 0.1331
Significance results were defined as a p value <0.05 and 95% confidence intervals that did not include 1.
Bracketed numbers following odds ratios or hazard ratios indicate 95% confidence intervals.
UnivarZ univariable; MultivarZ multivariable; CIZ confidence interval; PCZ prospective cohort; RCZ retrospective cohort; CNSZ cohort type not specified or determined from the
reported study; NS Z not significant (value not provided); NR Z not reported; OR Z odds ratio; HR Z hazard ratio.
a A cutoff value or number of units used for comparison was not explicitly defined.
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Table 11 Studies evaluating the relationship between survival and diffusing capacity of carbon monoxide in IPAH.
Study Association Comparison Measured value
(diffusing capacity)
Significance Study
Design
Number of
patients
D’alonzo4 þ Univar analysis
(Cox proportional
hazard model)
OR 0.97 (0.94, 0.99)
Per unit of measurement
(units not defined)
NR PC 194
D’alonzo4  Multivar analysis
(Cox proportional
hazard model)
OR 0.99 (0.96, 1.02) (model 1) NR PC 194
OR 0.96 (0.93, 1.00) (model 2)
OR 0.97 (0.94, 1.00) (model 3)
All per unit of measurement
(units not defined)
Paciocco23  Univar analysis
(Cox regression analysis)
HR 0.99 (0.93, 1.05)a P Z 0.74 PC 34
Significance results were defined as a p value <0.05 and 95% confidence intervals that did not include 1.
Diffusing capacity of carbon monoxide in reported mL min1 mmHg1
Bracketed numbers following odds ratios or hazard ratios indicate 95% confidence intervals.
Univar Z univariable; Multivar Z multivariable; PC Z prospective cohort; NR Z not reported; OR Z odds ratio; HR Z hazard ratio.
a A cutoff value or number of units used for comparison was not explicitly defined.
1604 J.R. Swiston et al.there were almost twice as many analyses that evaluated
this variable and did not find a significant association with
mortality compared to those that did find an association
with mortality. Mean RAP and PVR were the only hemody-
namic variables that had more supporting than non-sup-
porting analyses.
In 1980 the National Institutes of Health (NIH) established
a registry for primary pulmonary hypertension and prospec-
tively followed the natural history of this disease over a 5
year period in 194 patients.4 In an attempt to develop
a clinically useful means of prognosticating mortality in IPAH
the NIH registry cohort was retrospectively analyzed in 1991
at which time a number of variables associated with poor
survival were identified including higher New York Heart
Association functional class, the presence of Raynaud
phenomenon, elevated mRAP, elevate mPAP, decreased
cardiac index (CI), and a reduced DLCO.4 From this analysis
an equation was developed to predict survival base solely on
hemodynamic parameters (mRAP, mPAP pressure, and CI).
While the NIH equation is attractive in its simplicity,
validity represents a major concern with the use of this tool
to prognosticate mortality in IPAH. In 1994 Sandoval and
colleagues attempted to prospectively validate the NIH
formula in a cohort of 60 patients with primary pulmonary
hypertension (PPH)27 and found that while it was highly
sensitive at predicting survival in PPH, it lacked specificity.
Similarly, Appelbaum et al. compared the NIH projected and
actual survival times of 44 patients with PPH in Israel and
found a poor correlation between real and projected survival
times.29 In 1999 Okada et al. developed an alternate survival
equation based on retrospective survey of 223 PPH patients
in Japan.30 Unfortunately the Japanese equation has not
been prospectively validated and was not compared to the
NIH equation. More recently Thenappan et al. analyzed 282
patients with idiopathic, familial and anorexigen-associated
PAH in the Pulmonary Hypertension Connection registry and
found that survival in the current era is significantly better
than that predictedby theNIHequation.31 Theseauthors also
used their database to generate a new survival equation
(using the sameparameter ofmPAP,mRAP, andCI). However,
this new equation is yet to be prospectively validated. Morerecently the REVEAL Registry (Registry to Evaluate Early And
Long-term pulmonary arterial hypertension disease man-
agement) has been established to provide epidemiologic
data on the diagnosis, treatment, and management of PAH.
However, at the current time only baseline data has been
published and no mortality analysis has been reported in the
peer reviewed literature (Chest prepublished online 16 Oct
2009 doi:10.1378/chest.09-1140).
Both the NIH and the Japanese survival equations are
based primarily on hemodynamic parameters obtained on
right heart catheterization. The reliance on cardiac cath-
eterization data to prognosticate disease severity and
mortality is not optimal as this invasive procedure is not
without associated morbidity. Furthermore this procedure
is a costly and a limited resource in many health care
systems. Given these limitations, not only is initial assess-
ment more difficult but follow-up evaluations cannot
routinely include obtaining this hemodynamic data as
frequent re-catheterization is not feasible.
One of the greatest difficulties in comparing any given
prognostic factor across studies is the variability in the
analysis used. The most commonly employed method of
statistical analysis in the reviewed publications was the Cox
proportional hazard model. However, even within this
method there was significant variation in the techniques and
definitions employed. An example of this can be seen in the
evaluation of the 6MWD. Of the 10 studies identified that
evaluated this factor, 8 used the Cox proportional hazard
model. However, even within this method, one study used
a cutoff value of 332m,32 oneused 500 ft,18 one used 250m,15
one358m,33 twoused50m increments,34,35 and threedidnot
define the unit of analysis.19,25,36 Furthermore, some inves-
tigators,33,23,36,35 used a univariable analysis, while other
investigators32 reported the results of their multivariable
analysis only. Van Wolferen et al.19 found an association in
both the univariable and multivariable analysis, but both
Raymond et al.18 and Sitbon et al.15 found that this variable
was significant in their univariable analysis but the not the
multivariable analysis. These variations in analytical
methods and attendant findings make qualitative compari-
sons difficult and quantitative ones impossible.
Factors that prognosticate mortality in idiopathic pulmonary arterial hypertension 1605It is important to emphasize that studies that fail to
show a significant association do not necessarily provide
evidence for non-association on an individual basis. In
particular very few of these studies were specifically
designed or sufficiently powered to test a particular asso-
ciation. On the other hand, the identification of a signifi-
cant associated frequently occurred within the context of
studies that evaluated multiple factors simultaneously
without an a priori hypothesis stating the primary variable
of interest and without correcting for multiple compari-
sons. This places the studies at risk for a spurious
correlation.
Many studies evaluated in this review were excluded
because variables were explored in mixed populations of
PAH. Studies often include multiple subgroups of PAH
(category 1 of the Venice or Dana Point classification) in
their cohorts and subsequent analyses. Although this
approach may be appropriate in some therapeutic studies,
the validity of this practice when evaluating prognostic
factors is questionable. It is well known that survival curves
are not equivalent across all subgroups of category 1 PAH37
and therefore it should not be assumed that prognostic
variables will perform the same for these different
populations.
We did not perform a formal meta-analysis of the data.
There was significant heterogeneity across the studies with
regards to study populations, study design, analytical
techniques, and reporting of methods. It would be inap-
propriate to meta-analyze the data in the face of this
degree of heterogeneity.
We did not include surrogate markers of prognostic
variable in the synthesis of this review. For example a study
by Raeside et al.38 described a correlation between
cardiopulmonary exercise (CPET) parameters and mPAP but
was not included. If mPAP was conclusively shown to be
a predictor of early mortality, and CPET variables were
correlated with mPAP, than exercise testing may be a useful
tool for evaluation as it is a less invasive approach
compared to cardiac catheterization. However, as shown in
this review, the utility of mPAP is controversial and there-
fore it is premature to infer the value of CPET parameters
in predicting early mortality based on correlations with
mPAP rather than evaluating the predictive power of these
variables on mortality directly as was done by Wensel and
colleagues.21
Conclusion
IPAH is a severe and life limiting disease. The last two
decades have seen growing awareness of this condition,
improved understanding of IPAH pathophysiology, and the
development of multiple treatment options. Despite these
advances it remains difficult to accurately predict the
clinical course of IPAH patients and thus determine the
most appropriate strategy for monitoring, intervention, and
timely referral for lung transplantation. With the advent of
numerous potentially beneficial intervention strategies, the
need to identify those at greatest risk for adverse outcomes
has become increasingly important. There is a large body of
literature describing numerous factors that predict early
mortality in IPAH however consensus on the most valuable
factors has been hampered by disparate studies with smallsample sizes, mixed populations, the use of composite
endpoints, and variable study designs and analytical
methods. These discrepancies highlight the need to eval-
uate the literature in total when considering the utility of
variables as prognostic factors in IPAH.
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